An Early Phase 1 interventional study of ART002g1 Injection in Heterozygous Familial Hypercholesterolemia, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Hyperlipoproteinemia Type II with a site in China — 13 open to participants now, 13 under way, 7 of them phase 3. Hyperlipoproteinemia Type II · China.
Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, this one is the 18th largest by planned enrollment of the 22 interventional ones that give a count, is one of 6 that started in 2026, is one of 5 in phase 1, reaches primary completion later than 6 of the 12 other live ones, and was the 18th registered.
251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →13 of the 24 studies in Hyperlipoproteinemia Type II with a site in China are open now. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+ · Healthy volunteers
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+
Merck Sharp & Dohme LLC · Sites in China, United States, Australia and 17 more countries
Ages 6–17
Children's Hospital of Fudan University · Sites in China
Ages 1–3
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 37 Hyperlipoproteinemia Type II studies recruiting now, 17 (46%) set no upper age limit and 16 (43%) stop at 75 or younger; 17 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 14
First in 2018; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 131 across 180 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 142 across the 22 interventional studies, 8,064 across the 2 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 24 have an industry lead sponsor. The 10 most frequent:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 182 studies on the registry; 108 are open to participants now.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine has 1 study filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
3 of the studies in Hyperlipoproteinemia Type II with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05043181Tang-Du HospitalExosome-based Nanoplatform for Ldlr mRNA Delivery in FH | 2026-12 |
| NCT07695597CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia | 2027-04-30 |
| NCT07353398Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineEarly-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an open-label, single ascending dose (SAD) study designed to evaluate the safety and tolerability of ART002g1 in patients with heterozygous familial hypercholesterolemia (HeFH) who require further reduction in low-density lipoprotein cholesterol (LDL-C). ART002g1 uses base editing technology, which is designed to interfere with the expression of the PCSK9 gene in the liver, thereby reducing the circulating levels of PCSK9 and LDL-C. The primary objectives of this study are to determine the safety and pharmacodynamic (PD) profiles of ART002g1 in this patient population.
Subjects must meet all the following criteria to be eligible for enrollment:
(1) HeFH diagnosed to be caused by mutations in the LDLR, APOB, or PCSK9 gene;
(2) Meeting 2 out of the 3 following criteria for adults per the Dutch Lipid Clinical Network (DLCN) criteria:
Subjects must not be enrolled if they meet any one or more of the following exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of ART002g1.
Drug: ART002g1 Injection
Participants will receive a single dose of ART002g1.
Drug: ART002g1 Injection
Participants will receive a single Optimal Biological Dose (OBD) of ART002g1, which is based on the results of the ascending dose escalation.
Drug: ART002g1 Injection
Intravenous (IV) infusion
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: As of Week 48 (W48) post-administration of ART002g1 for Injection
Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1: Tmax
Time frame: As of Week 2 (W2) post-administration of ART002g1 for Injection
Pharmacodynamic (PD) Assessments: Serum PCSK9 protein
Time frame: As of Week 48 (W48) post-administration of ART002g1 for Injection
Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1: Cmax
Time frame: As of Week 2 (W2) post-administration of ART002g1 for Injection
Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1: AUC
Time frame: As of Week 2 (W2) post-administration of ART002g1 for Injection
Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1: t½
Time frame: As of Week 2 (W2) post-administration of ART002g1 for Injection
Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1: CL
Time frame: As of Week 2 (W2) post-administration of ART002g1 for Injection
Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1:Vss
Time frame: As of Week 2 (W2) post-administration of ART002g1 for Injection
Pharmacodynamic (PD) Assessments: Serum LDL-C
Time frame: As of Week 48 (W48) post-administration of ART002g1 for Injection
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Jul 2027, 16 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperlipoproteinemia Type II →
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine →